The DOI matches its Crossref record; 80 of the 81 references it cites were found in a registry or an index.
LSD enhances suggestibility in healthy volunteers
Abstract
Rationale Lysergic acid diethylamide (LSD) has a history of use as a psychotherapeutic aid in the treatment of mood disorders and addiction, and it was also explored as an enhancer of mind control. Objectives The present study sought to test the effect of LSD on suggestibility in a modern research study. Methods Ten healthy volunteers were administered with intravenous (i.v.) LSD (40-80 μg) in a within-subject placebo-controlled design. Suggestibility and cued mental imagery were assessed using the Creative Imagination Scale (CIS) and a mental imagery test (MIT). CIS and MIT items were split into two versions (A and B), balanced for 'efficacy' (i.e. A ≈ B) and counterbalanced across conditions (i.e. 50 % completed version 'A' under LSD). The MIT and CIS were issued 110 and 140 min, respectively, post-infusion, corresponding with the peak drug effects. Results Volunteers gave significantly higher ratings for the CIS (p = 0.018), but not the MIT (p = 0.11), after LSD than placebo. The magnitude of suggestibility enhancement under LSD was positively correlated with trait conscientiousness measured at baseline (p = 0.0005). Conclusions These results imply that the influence of suggestion is enhanced by LSD. Enhanced suggestibility under LSD may have implications for its use as an adjunct to psychotherapy, where suggestibility plays a major role. That cued imagery was unaffected by LSD implies that suggestions must be of a sufficient duration and level of detail to be enhanced by…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The first study, which was limited by a small sample of 10 healthy volunteers, showed that LSD (40–80 µg, i.v.) enhances suggestibility on the Creative Imagination Scale, while Cued Imagery remained unaffected (83).”
From Modulation of Social Cognition via Hallucinogens and “Entactogens” (2019) · cites this paper as [83]
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
Selective Cortical Undercutting As a Means of Modifying and Studying Frontal Lobe Function in Man
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,374
Validation of the five-factor model of personality across instruments and observers.
McCrae, R. R., & Costa, P. T. (1987) · Journal of Personality and Social Psychology · doi:10.1037/0022-3514.52.1.81 · Cited by 6,404
Tellegen, A., & Atkinson, G. (1974) · Journal of Abnormal Psychology · doi:10.1037/h0036681 · Cited by 2,196
Carhart-Harris, R. L., Leech, R., Hellyer, P. J., Shanahan, M., Feilding, A., Tagliazucchi, E., Chialvo, D. R., & Nutt, D. (2014) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2014.00020 · Cited by 1,252
Self-citationNichols, D. E. (2004) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2003.11.002 · Cited by 1,211
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Gasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
Evidence for 5-HT2 involvement in the mechanism of action of hallucinogenic agents
Glennon, R. A., Titeler, M., & MCKENNEY, J. D. J. (1984) · Life Sciences · doi:10.1016/0024-3205(84)90436-3 · Cited by 635
Research works printed but not linked: 2
- Grof S (1980) LSD Psychotherapy. Hunter House, US
- Weitzenhoffer AM, Hilgard ER (1959) Stanford hypnotic susceptibility scale, for use in research investigations in the field of hypnotic phenomena. Consulting Psychologists, Palo Alto
Cited by
Sorted by citations
Items 101–200 of 319
Seeing without self: Discovering new meaning with psychedelic-assisted psychotherapy
Fischman, L. G. (2019) · Neuropsychoanalysis · doi:10.1080/15294145.2019.1689528 · Cited by 52
The need for establishing best practices and gold standards in psychedelic medicine
Feduccia, A. A., Agin-Liebes, G., Price, C. M., Grinsell, N., Paradise, S., & Rabin, D. M. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.03.083 · Cited by 44
Clinical specificity profile for novel rapid acting antidepressant drugs
Scala, M., Fanelli, G., De Ronchi, D., Serretti, A., & Fabbri, C. (2023) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000488 · Cited by 41
Relational Processes in Ayahuasca Groups of Palestinians and Israelis
Roseman, L., Ron, Y., Saca, A., Ginsberg, N. L., Luan, L. X., Karkabi, N., Doblin, R., & Carhart-Harris, R. L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.607529 · Cited by 43
Self-citationVilliger, D., & Trachsel, M. (2023) · Journal of Medical Ethics · doi:10.1136/jme-2022-108816 · Cited by 43
Current Perspective on the Therapeutic Preset for Substance-Assisted Psychotherapy
Thal, S. B., Bright, S. J., Sharbanee, J. M., Wenge, T., & Skeffington, P. (2021) · Frontiers in Psychology · doi:10.3389/fpsyg.2021.617224 · Cited by 38
Do psychedelics change beliefs?
McGovern, H. T., Leptourgos, P., Hutchinson, B. T., & Corlett, P. R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06153-1 · Cited by 40
Moral Psychopharmacology Needs Moral Inquiry: The Case of Psychedelics
Langlitz, N., Dyck, E., Scheidegger, M., & Repantis, D. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.680064 · Cited by 41
A Systematic Review of Study Design and Placebo Controls in Psychedelic Research
Wen, A. Q., Singhal, N., Jones, B. D. M., Zeifman, R. J., Mehta, S. H., Shenasa, M. A., Blumberger, D. M., Daskalakis, Z. J., & Weissman, C. R. (2023) · Psychedelic Medicine · doi:10.1089/psymed.2023.0028 · Cited by 42
A framework for assessment of adverse events occurring in psychedelic-assisted therapies
Palitsky, R., Kaplan, D. M., Perna, J., Bosshardt, Z., Maples‐Keller, J. L., Levin-Aspenson, H. F., Zarrabi, A. J., Peacock, C., Mletzko, T., Rothbaum, B. O., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241265756 · Cited by 47
Duerler, P., Schilbach, L., Stämpfli, P., Vollenweider, F. X., & Preller, K. H. (2020) · Scientific Reports · doi:10.1038/s41598-020-68899-y · Cited by 38
Psilocybin and Other Classic Psychedelics in Depression
Nutt, D., Peill, J. M., Weiss, B., Godfrey, K., Carhart-Harris, R. L., & Erritzøe, D. (2023) · Current topics in behavioral neurosciences · doi:10.1007/7854_2023_451 · Cited by 39
Self-citationKurtz, J. S., Patel, N., Gendreau, J. L., Yang, C., Brown, N. J., Bui, N., Picton, B., Harris, M., Hatter, M. J., Beyer, R. S., et al. (2022) · Cureus · doi:10.7759/cureus.29167 · Cited by 40
Harnessing placebo: Lessons from psychedelic science
Pronovost-Morgan, C., Hartogsohn, I., & Ramaekers, J. G. (2023) · Journal of Psychopharmacology · doi:10.1177/02698811231182602 · Cited by 39
Doss, M. K., de Wit, H., & Gallo, D. A. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105188 · Cited by 37
McIntyre, R. S., Kwan, A. T. H., Mansur, R. B., Oliveira-Maia, A. J., Teopiz, K. M., Maletic, V., Suppes, T. M., Stahl, S. M., & Rosenblat, J. D. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230902 · Cited by 33
Reynolds, L., Akroyd, A., Sundram, F., Stack, A., Muthukumaraswamy, S. D., & Evans, W. J. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18158160 · Cited by 37
Garel, N., Lévesque, J. T., Sandra, D. A., Lessard-Wajcer, J., Solomonova, E., Lifshitz, M., Richard‐Devantoy, S., & Greenway, K. T. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1200393 · Cited by 33
Giving Consent to the Ineffable
Villiger, D. (2024) · Neuroethics · doi:10.1007/s12152-024-09545-6 · Cited by 32
Psychedelic Therapy as Form of Life
Langlitz, N., & Gearin, A. K. (2024) · Neuroethics · doi:10.1007/s12152-024-09550-9 · Cited by 31
Dolder, P. C., Liechti, M. E., & Rentsch, K. (2017) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22265 · Cited by 31
Maij, D. L. R., van Elk, M., & Schjoedt, U. (2017) · Religion Brain & Behavior · doi:10.1080/2153599x.2017.1403952 · Cited by 33
New Frontiers or a Bursting Bubble? Psychedelic Therapy Beyond the Dichotomy
Noorani, T. N., & Martell, J. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.727050 · Cited by 37
Psychedelics alter metaphysical beliefsPreprint
Timmermann, C., Kettner, H., Letheby, C., Roseman, L., Rosas, F. E., & Carhart-Harris, R. L. (2021) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/f6sjk · Cited by 34
Self-citationPsychedelic Cognition—The Unreached Frontier of Psychedelic Science
Bălăeţ, M. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.832375 · Cited by 34
Engel, L. B., Thal, S. B., & Bright, S. J. (2022) · Contemporary Drug Problems · doi:10.1177/00914509221121420 · Cited by 30
New Paradigms of Old Psychedelics in Schizophrenia
Mahmood, D., Alenezi, S. K., Anwar, M. J., Azam, F., Qureshi, K. A., & Jaremko, M. (2022) · Pharmaceuticals · doi:10.3390/ph15050640 · Cited by 29
A Transformative Trip? Experiences of Psychedelic Use
Neitzke‐Spruill, L., Beit, C. S., Robinson, J. O., Blevins, K. R., Reynolds, J., Evans, N. G., & McGuire, A. L. (2024) · Neuroethics · doi:10.1007/s12152-024-09567-0 · Cited by 30
Psychedelics and hypnosis: Commonalities and therapeutic implications
Lemercier, C. E., & Terhune, D. B. (2018) · Journal of Psychopharmacology · doi:10.1177/0269881118780714 · Cited by 32
History repeating: A roadmap to address common problems in psychedelic sciencePreprint
van Elk, M., & Fried, E. I. (2023) · doi:10.31234/osf.io/ak6gx · Cited by 30
Buchborn, T., Kettner, H., Kärtner, L., & Meinhardt, M. W. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1232459 · Cited by 30
Thal, S. B., Baker, P., Marinis, J., Wieberneit, M., Sharbanee, J. M., Bruno, R., Skeffington, P., & Bright, S. J. (2023) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.2945 · Cited by 32
Peacock, C., Mascaro, J. S., Brauer, E., Zarrabi, A. J., Dunlop, B. W., Maples‐Keller, J. L., Grant, G. H., Raison, C. L., Rab, F., & Palitsky, R. (2024) · PLoS ONE · doi:10.1371/journal.pone.0296071 · Cited by 32
Irvine, A., & Luke, D. P. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00195 · Cited by 25
Psychedelics as potential catalysts of scientific creativity and insight
Gandy, S., Bonnelle, V., Jacobs, E., & Luke, D. P. (2022) · Drug Science Policy and Law · doi:10.1177/20503245221097649 · Cited by 31
Bonnelle, V., Smith, W., Mason, N. L., Cavarra, M., Kryskow, P., Kuypers, K. P. C., Ramaekers, J. G., & Feilding, A. (2022) · British Journal of Pain · doi:10.1177/20494637221114962 · Cited by 26
Self-citationPadawer-Curry, J. A., Krentzman, O. J., Kuo, C., Wang, X., Bice, A. R., Nicol, G. E., Snyder, A. Z., Siegel, J. S., McCall, J. G., & Bauer, A. Q. (2025) · Nature Neuroscience · doi:10.1038/s41593-025-02069-z · Cited by 30
Heinzerling, K. G., Sergi, K., Linton, M., Rich, R., Youssef, B., Bentancourt, I., Bramen, J. E., Siddarth, P., Schwartzberg, L., & Kelly, D. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1215972 · Cited by 25
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Baker, P., Bruno, R., Wenge, T., & Bright, S. J. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221127954 · Cited by 24
Predictors and potentiators of psychedelic-occasioned mystical experiences
Gandy, S. (2022) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00198 · Cited by 32
Lewis, B. R., Byrne, K., Hendrick, J., Garland, E. L., Thielking, P. D., & Beck, A. C. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2022.00222 · Cited by 23
Kruger, D. J., Aday, J. S., Fields, C. W., Kolbman, N., Glynos, N. G., Barron, J., Herberholz, M., & Boehnke, K. F. (2024) · Psychedelic Medicine · doi:10.1089/psymed.2024.0011 · Cited by 24
The neurochemistry of hypnotic suggestion
Acunzo, D. J., Oakley, D. A., & Terhune, D. B. (2021) · American Journal of Clinical Hypnosis · doi:10.1080/00029157.2020.1865869 · Cited by 25
Set and setting in microdosing: an oft-overlooked principle
Hartogsohn, I., & Petranker, R. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06249-8 · Cited by 26
Family, N., Hendricks, P. S., Williams, L. T. J., Luke, D. P., Maillet, É. L., Maillet, É. L., & Raz, S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211069103 · Cited by 23
Psychedelic-assisted psychotherapy, patient vulnerability and abuses of power
Meikle, S. E., Carter, O. L., & Bedi, G. (2023) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/00048674231200164 · Cited by 25
The future of psychiatry: clinical practice, diagnosis, and treatment
Turner, S., Yadav, P., Morrin, H., & Bhat, A. (2025) · International Review of Psychiatry · doi:10.1080/09540261.2025.2594523 · Cited by 23
Scacchia, P., & Pascalis, V. D. (2020) · American Journal of Clinical Hypnosis · doi:10.1080/00029157.2019.1586639 · Cited by 21
Being for no-one: Psychedelic experience and minimal subjectivity
Letheby, C. (2020) · Philosophy and the Mind Sciences · doi:10.33735/phimisci.2020.i.47 · Cited by 20
How Psychedelics Modulate Multiple Memory Mechanisms in Posttraumatic Stress Disorder
Doss, M. K., DeMarco, A., Dunsmoor, J. E., Cisler, J. M., Fonzo, G. A., & Nemeroff, C. B. (2024) · Drugs · doi:10.1007/s40265-024-02106-4 · Cited by 24
Psychedelics and the ‘inner healer’: Myth or mechanism?
Peill, J. M., Marguilho, M., Erritzøe, D., Barba, T., Greenway, K. T., Rosas, F. E., Timmermann, C., & Carhart-Harris, R. L. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241239206 · Cited by 24
Self-citationDo psychedelics facilitate emergence of unconscious psychological processes
Lindegaard, T. (2023) · Psychodynamic Psychiatry · doi:10.1521/pdps.2023.51.3.270 · Cited by 18
Mayer, C. E., LeBaron, V. T., & Acquaviva, K. (2021) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2021.1916659 · Cited by 18
Remembering Molly: Immediate and delayed false memory formation after acute MDMA exposure
Kloft, L., Otgaar, H., Blokland, A., Toennes, S. W., & Ramaekers, J. G. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.01.005 · Cited by 19
How Psychedelic-Assisted Treatment Works in the Bayesian Brain
Villiger, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.812180 · Cited by 21
Psychedelics in the Treatment of Headache and Chronic Pain Disorders
Schindler, E. A. D. (2022) · Current topics in behavioral neurosciences · doi:10.1007/7854_2022_365 · Cited by 19
The psychedelic ritual as a technique of the self
Dupuis, D. (2022) · Hau Journal of Ethnographic Theory · doi:10.1086/719792 · Cited by 17
Walther, R. F. E., & van Schie, H. T. (2024) · Psychoactives · doi:10.3390/psychoactives3030026 · Cited by 20
Hypnotic suggestions of safety reduce neuronal signals of delay discounting
Schmidt, B. K., & Holroyd, C. B. (2021) · Scientific Reports · doi:10.1038/s41598-021-81572-2 · Cited by 19
Daldegan‐Bueno, D., Révész, D., Morais, P. R., Barbosa, P. C. R., & Maia, L. O. (2022) · Substance Use & Misuse · doi:10.1080/10826084.2022.2063896 · Cited by 20
Neural and subjective effects of inhaled DMT in natural settingsPreprint
Pallavicini, C., Cavanna, F., Zamberlán, F., de la Fuente, L. A., Perl, Y. S., Arias, M., Romero, C., Carhart-Harris, R. L., Timmermann, C., & Tagliazucchi, E. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.19.258145 · Cited by 17
Self-citationSynthetic surprise as the foundation of the psychedelic experience
Filippo, R. D., & Schmitz, D. (2024) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2024.105538 · Cited by 17
Experiential Training in Psychedelic‐Assisted Therapy: A Risk‐Benefit Analysis
Rosenbaum, D., Hare, C., Hapke, E., Herman, Y., Abbey, S. E., Sisti, D. A., & Buchman, D. Z. (2024) · The Hastings Center Report · doi:10.1002/hast.1602 · Cited by 18
Schifano, F., Napoletano, F., Chiappini, S., Orsolini, L., Guirguis, A., Corkery, J., Bonaccorso, S., Ricciardi, A., Scherbaum, N., & Vento, A. E. (2019) · Current Addiction Reports · doi:10.1007/s40429-019-00249-z · Cited by 19
Further education in psychedelic-assisted therapy – experiences from Switzerland
Aicher, H., Müller, F., & Gasser, P. (2025) · BMC Medical Education · doi:10.1186/s12909-025-06871-y · Cited by 18
The association between naturalistic use of psychedelics and co-occurring substance use disorders
Rabinowitz, J., Lev‐Ran, S., & Gross, R. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.1066369 · Cited by 15
Geagea, D., Ogez, D., Kimble, R. M., & Tyack, Z. F. (2023) · Complementary Therapies in Clinical Practice · doi:10.1016/j.ctcp.2023.101776 · Cited by 19
Stewart, B., Dean, J. G., Koek, A. Y., Chua, J. P., Wabl, R., Martin, K., Davoodian, N., Becker, C. J., Himedan, M., Kim, A., et al. (2020) · Pharmacology Research & Perspectives · doi:10.1002/prp2.688 · Cited by 14
Nicholas, C. R. N., Banks, M. I., Lennertz, R. C., Wenthur, C. J., Krause, B. M., Riedner, B. A., Smith, R., Hutson, P. R., Sauder, C. J., Dunne, J. D., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-03059-8 · Cited by 13
How to Make Psychedelic-Assisted Therapy Safer
Villiger, D. (2024) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180124000604 · Cited by 13
Psychedelics and autobiographical memory – six open questions
Kangaslampi, S., & Lietz, M. P. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06771-5 · Cited by 14
Pattern Breaking: A Complex Systems Approach to Psychedelic MedicinePreprint
Hipólito, I., Mago, J., Rosas, F. E., & Carhart-Harris, R. L. (2022) · doi:10.31234/osf.io/ydu3h · Cited by 13
Self-citationTolerance to Lysergic Acid Diethylamide
Buchborn, T., Grecksch, G., Dieterich, D. C., & Höllt, V. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00079-0 · Cited by 12
Long-lasting analgesic effect of the psychedelic drug changa: A case report
Oña, G., & Troncoso, S. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.001 · Cited by 12
A Systematic Study of Microdosing PsychedelicsPreprint
Polito, V., & Stevenson, R. J. (2018) · PsyArXiv (OSF Preprints) · doi:10.31234/osf.io/cw9qs · Cited by 13
LSD acutely impairs fear recognition and enhances emotional empathy and sociality
Dolder, P. C. (2016) · doi:10.26226/morressier.5785edc6d462b80296c9935b · Cited by 13
The Induction of Synaesthesia in Non-Synaesthetes
Terhune, D. B., Luke, D. P., & Kadosh, R. C. (2017) · Oxford University Press eBooks · doi:10.1093/oso/9780199688289.003.0012 · Cited by 12
Bright, S. J., & Williams, M. L. (2018) · Australian Psychologist · doi:10.1111/ap.12345 · Cited by 12
Healing, Harms, and Humility: Expanding the Scope of Psychedelic-Assisted Psychotherapy Research
O’Donnell, K. C., Grigsby, J., & Grob, C. S. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230785 · Cited by 11
Yaden, D. B., Graziosi, M., Owen, A. M., Agin-Liebes, G., Aaronson, S. T., Allen, K. E., Barrett, F. S., Bogenschutz, M. P., Carhart-Harris, R. L., Ching, T. H. W., et al. (2025) · Psychedelic Medicine · doi:10.1089/psymed.2024.0019 · Cited by 12
Self-citationButler, M., Bird, C., Maggio, C., Durden, A., Modlin, N. L., Campbell‐Coker, K., Edwards, M. J., Pick, S., Millman, L. S. M., Lowery, E., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22543.1 · Cited by 9
Epistemic Risk Reduction in Psychedelic-Assisted Therapy
Caporuscio, C., & Fink, S. B. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_531 · Cited by 9
Guruism and Cultic Social Dynamics in Psychedelic Practices and Organisations
Evans, J., & Adams, J. H. (2024) · Current topics in behavioral neurosciences · doi:10.1007/7854_2024_535 · Cited by 10
Thal, S. B., Daniels, J. K., & Jungaberle, H. (2019) · Journal of Substance Use · doi:10.1080/14659891.2019.1614234 · Cited by 9
Thal, S. B., Engel, L. B., & Bright, S. J. (2022) · Addiction Research & Theory · doi:10.1080/16066359.2022.2065268 · Cited by 9
Transcultural Factors in Hypnotizability Scales: Limits and Prospects
Champigny, C. M., & Raz, A. (2015) · American Journal of Clinical Hypnosis · doi:10.1080/00029157.2015.1061473 · Cited by 10
EMBARK Psychedelic Therapy for Depression
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Harms, A. (2021) · Anthropology of Consciousness · doi:10.1111/anoc.12130 · Cited by 8
Hendricks, P. S., Copes, H., Family, N., Williams, L. T. J., Luke, D. P., & Raz, S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211055855 · Cited by 9
Psychedelika und Dissoziativa in der Psychiatrie: Herausforderungen in der Behandlung
Jungwirth, J., Bavato, F., & Quednow, B. B. (2024) · Der Nervenarzt · doi:10.1007/s00115-024-01727-0 · Cited by 7
Doss, M. K., Kloft, L., Mason, N. L., Mallaroni, P., Reckweg, J. T., van Oorsouw, K. I. M., Tupper, N., Otgaar, H., & Ramaekers, J. G. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241301216 · Cited by 8
The Role and Ethics of Touch and Non-touch in Psychedelic-Assisted Therapy
Aicher, H., Röskamp, A., Moser, M., & Brand, M. (2025) · Current topics in behavioral neurosciences · doi:10.1007/7854_2025_608 · Cited by 7
Ayahuasca ceremony leaders’ perspectives on special considerations for eating disorders
Williams, M., Miller, A. K., & Lafrance, A. (2023) · Eating Disorders · doi:10.1080/10640266.2023.2271201 · Cited by 7
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 1
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Bruno, R., Wenge, T., & Bright, S. J. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231168516 · Cited by 9
LIMITATIONS ON THE SCIENTIFIC STUDY OF DRUG‐ENABLED MYSTICAL EXPERIENCES
Jones, R. H. (2019) · Zygon® · doi:10.1111/zygo.12546 · Cited by 7
Virtual Daime: When Psychedelic Ritual Migrates Online
Hartogsohn, I. (2022) · Frontiers in Psychology · doi:10.3389/fpsyg.2022.819994 · Cited by 8
Pendse, S. R., Kumar, N., & Choudhury, M. D. (2024) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3613904.3642477 · Cited by 8
Psychedelics, attachment, and enculturation dynamics: Prospects and challenges
Cassidy, E. K., Dupuis, D., Timmermann, C., & Granqvist, P. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00459 · Cited by 7
Chwyl, C., Wilson‐Poe, A. R., Hoffman, K. A., Bazinet, A. D., Pertl, K., Luoma, J. B., Jarlais, D. C. D., Bielavitz, S., & Korthuis, P. T. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104938 · Cited by 7
Metadata
- Authors
- Carhart-Harris, R. L., Kaelen, M., Whalley, M. G., Bolstridge, M., Feilding, A., & Nutt, D. J.
- Affiliations
- Imperial College London (GB)
- Royal Berkshire NHS Foundation Trust (GB)
- Beckley Foundation (GB)
- Corresponding author
- Carhart-Harris, R. L.
- Venue
- Psychopharmacology
- Published
- 2014-09-23
- Volume
- 232
- Issue
- 4
- Pages
- 785-794
- ISSN
- 0033-3158 (ISSN-L)
- 1432-2072
- OpenAlex
- W2037317432
- Cited by
- 320
- References
- 81
- Citations by year
- 2026: 25 · 2025: 40 · 2024: 52 · 2023: 36 · 2022: 40 · 2021: 38 · 2020: 19 · 2019: 13 · 2018: 18 · 2017: 15 · 2016: 18 · 2015: 4 · 2014: 1
- FWCI
- 14.95
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Psychopharmacology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- Beckley Foundation
- National Institute for Health and Care Research
- Medical Research Council (MR/J00460X/1)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Neuroscience › Cognitive Neuroscience › Pain Management and Placebo Effect
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- lysergic acid diethylamide, LSD, suggestibility, psychedelic effects, mind control, psychotherapy adjunct
- MeSH terms
- Adult, Affect, Dose-Response Relationship, Drug, Hallucinogens, Humans, Imagination, Infusions, Intravenous, Lysergic Acid Diethylamide, Male, Placebos, Suggestion, Single-Blind Method, Healthy Volunteers
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review